No Effect of Pyridoxine on the Incidence of Myelosuppression during Prolonged Linezolid Treatment | Zendy

Diamantis Plachouras | Zendy; Efthymia Giannitsioti | Zendy; Sofia Athanassia | Zendy; Flora Kontopidou | Zendy; A Papadopoulos | Zendy; K. Kanellakopoulou | Zendy; Helen Giamarellou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

No Effect of Pyridoxine on the Incidence of Myelosuppression during Prolonged Linezolid Treatment

Author(s) -

Diamantis Plachouras,

Efthymia Giannitsioti,

Sofia Athanassia,

Flora Kontopidou,

A Papadopoulos,

K. Kanellakopoulou,

Helen Giamarellou

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/508280

Subject(s) - pyridoxine , medicine , linezolid , incidence (geometry) , anemia , gastroenterology , vancomycin , biology , bacteria , genetics , staphylococcus aureus , physics , optics

Complications of long-term linezolid administration include anemia and thrombocytopenia. A recent report has suggested that pyridoxine may prevent myelosuppression. Pyridoxine was administered to 24 patients with bone infections who were being treated with linezolid. Thrombocytopenia occurred in 11 patients (45.8%), and anemia occurred in 6 (25%). We concluded that treatment wtih pyridoxine is unlikely to benefit patients who have been receiving linezolid for >2 weeks.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research